<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(2)</volume><submitter>Singh KA</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Idiosyncratic drug-induced liver injury (iDILI) causing acute liver failure (ALF) carries high short-term mortality and patients who meet King's College criteria for liver transplantation have 1-month survival of 34% without liver transplantation (PMID: 20949552). We present our experience with low-volume plasma exchange (PLEX-LV, 50% of estimated plasma volume exchanged per session) and low-dose steroid to treat iDILI ALF.&lt;h4>Methods&lt;/h4>We retrospectively analysed data of patients with iDILI (diagnosed as per RUCAM score), treated with PLEX-LV and low-dose steroid (prednisolone: 10 mg OD, with rapid taper) in our department from 2016 to 2022. Baseline and dynamic parameters (post-PLEX) were assessed as predictors of 1-month liver transplantation-free survival.&lt;h4>Results&lt;/h4>Twenty-two iDILI patients [probable: possible iDILI: 20:2, males: 9, age: 30 (14-84) years, median (range); MELD score: 30.5 (19-43)] underwent PLEX-LV for ALF during the study period. Causative agents were complementary and alternative medications (36%), antiepileptics (18%) antimicrobials (14%), antitubercular drugs (14%), antifungal drugs (9%) and others (9%). All patients had jaundice and encephalopathy; 9 patients also had ascites. None of the patients underwent liver transplantation. Study patients underwent 3 (1-7) PLEX sessions and 1.4 (0.6-1.6) litres of plasma was exchanged per session. One-month transplant-free survival was 59% (13/22) in the study population and 63% (12/19) among patients who fulfilled Kings College criteria for liver transplantation. Reduction of ≥25% in plasma von Willebrand factor (VWF) levels after PLEX-LV predicted improved survival (HR: 0.09, 95% CI: 0.01-0.65; AUROC: 0.81; 95% CI: 0.6-1.0).&lt;h4>Conclusion&lt;/h4>Low-volume PLEX and low-dose steroid appears a promising treatment option in patients with iDILI-induced ALF not opting for liver transplantation. Dynamic changes in VWF level after PLEX predict 1-month survival in these patients.</pubmed_abstract><journal>Journal of clinical and experimental hepatology</journal><pagination>101303</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10698001</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Single-Centre Experience With Low-Volume Plasma Exchange and Low-Dose Steroid to Treat Patients With Idiosyncratic Drug-Induced Acute Liver Failure.</pubmed_title><pmcid>PMC10698001</pmcid><pubmed_authors>Kumar SE</pubmed_authors><pubmed_authors>Goel A</pubmed_authors><pubmed_authors>Zachariah UG</pubmed_authors><pubmed_authors>David V</pubmed_authors><pubmed_authors>Pichamuthu K</pubmed_authors><pubmed_authors>Daniel D</pubmed_authors><pubmed_authors>Eapen CE</pubmed_authors><pubmed_authors>Singh KA</pubmed_authors><pubmed_authors>Jacob E</pubmed_authors><pubmed_authors>Kodiatte TA</pubmed_authors><pubmed_authors>Subramani K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Single-Centre Experience With Low-Volume Plasma Exchange and Low-Dose Steroid to Treat Patients With Idiosyncratic Drug-Induced Acute Liver Failure.</name><description>&lt;h4>Background&lt;/h4>Idiosyncratic drug-induced liver injury (iDILI) causing acute liver failure (ALF) carries high short-term mortality and patients who meet King's College criteria for liver transplantation have 1-month survival of 34% without liver transplantation (PMID: 20949552). We present our experience with low-volume plasma exchange (PLEX-LV, 50% of estimated plasma volume exchanged per session) and low-dose steroid to treat iDILI ALF.&lt;h4>Methods&lt;/h4>We retrospectively analysed data of patients with iDILI (diagnosed as per RUCAM score), treated with PLEX-LV and low-dose steroid (prednisolone: 10 mg OD, with rapid taper) in our department from 2016 to 2022. Baseline and dynamic parameters (post-PLEX) were assessed as predictors of 1-month liver transplantation-free survival.&lt;h4>Results&lt;/h4>Twenty-two iDILI patients [probable: possible iDILI: 20:2, males: 9, age: 30 (14-84) years, median (range); MELD score: 30.5 (19-43)] underwent PLEX-LV for ALF during the study period. Causative agents were complementary and alternative medications (36%), antiepileptics (18%) antimicrobials (14%), antitubercular drugs (14%), antifungal drugs (9%) and others (9%). All patients had jaundice and encephalopathy; 9 patients also had ascites. None of the patients underwent liver transplantation. Study patients underwent 3 (1-7) PLEX sessions and 1.4 (0.6-1.6) litres of plasma was exchanged per session. One-month transplant-free survival was 59% (13/22) in the study population and 63% (12/19) among patients who fulfilled Kings College criteria for liver transplantation. Reduction of ≥25% in plasma von Willebrand factor (VWF) levels after PLEX-LV predicted improved survival (HR: 0.09, 95% CI: 0.01-0.65; AUROC: 0.81; 95% CI: 0.6-1.0).&lt;h4>Conclusion&lt;/h4>Low-volume PLEX and low-dose steroid appears a promising treatment option in patients with iDILI-induced ALF not opting for liver transplantation. Dynamic changes in VWF level after PLEX predict 1-month survival in these patients.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar-Apr</publication><modification>2025-04-04T02:45:29.43Z</modification><creation>2025-04-04T02:45:29.43Z</creation></dates><accession>S-EPMC10698001</accession><cross_references><pubmed>38076447</pubmed><doi>10.1016/j.jceh.2023.11.003</doi></cross_references></HashMap>